N-terminal modification is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-10. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
Carroll, J. T. (1975). Ireland in the War Years 1939–1945. David and Charles. ISBN 9780844805658. Coogan, Tim Pat (1993). De Valera: Long Fellow, Long Shadow. London: Hutchinson. ISBN 9780091750305. published as Eamon de Valera: The Man Who Was Ireland (New York, 1993) Coogan, Tim Pat (1990). Michael Collins. Hutchinson. ISBN 0-09-174106-8. Corcoran, Donal. "Public policy in an emerging state: The Irish Free State 1922-25." Irish Journal of Public Policy 1.1 (2009). online Dwyer, T. Ryle (2006). Big Fellow, Long Fellow: A Joint Biography of Collins and De Valera. Gill Books. ISBN 0717140849. excerpt and text search Dwyer, T. Ryle (1982). De Valera's Finest Hour 1932–59. Fanning, Ronan. Éamon de Valera: A Will to Power (2016) Foster, R. F. Modern Ireland, 1600-1972 (1989) online Girvin, Brian. "Beyond Revisionism? Some Recent Contributions to the Study of Modern Ireland." The English Historical Review 124#506, 2009, pp. 94–107. online Gwynn, Denis. The Irish Free State, 1922-1927 (Macmillan 1928); detailed coverage.online Keown, Gerard. First of the Small Nations: The Beginnings of Irish Foreign Policy in the Inter-war Years, 1919-1932 (Oxford University Press, 2016). online Kissane, Bill. "Eamon De Valera and the Survival of Democracy in Inter-War Ireland". Journal of Contemporary History (2007). 42 (2): 213–226. online Lee, J. J. Ireland, 1912-1985: politics and society (Cambridge University Press, 1989) online. McCardle, Dorothy (January 1999). The Irish Republic. Wolfhound Press. ISBN 0-86327-712-8. O'Halpin, Eunan.
Lithium ascorbate is a salt of lithium with an organic anion, ascorbate. It is used as a component of lithium-containing food supplements. Pharmacotherapy of bipolar disorder widely employs lithium carbonate for more than 60 years. The toxicity of the latter (LD50 = 525 mg/kg per os) stimulates search for effective and non-toxic lithium salts. A chemoreactomic screening of 1245 water-soluble lithium salts with organic anions made it possible to identify 11 low-toxic lithium salts (LD50 > 1000 mg/kg) with high bioavailability (>20%: ascorbate, nicotinate, hydroxybutyrate, orotate, citrate, gluconate, comenate, pyroglutamate, glycinate, asparaginate, lactate). Among these, lithium ascorbate was characterized by more prominent inhibition of serotonin and dopamine reuptake and by an affinity for inhibition of glutamate and beta-adrenergic receptors. Chemoreactomic analysis showed that lithium ascorbate can also be characterized by anti-inflammatory action (due to the modulation of prostaglandin metabolism), have moderate anticoagulant, antihyperlipidemic, antihyperglycemic and antitumor effects. Biodistribution and toxicity have been studied in experimental and clinical studies; the antioxidant, neuroprotective, antitumor and adaptogenic effects of lithium ascorbate have been confirmed.
The phenomenon of multiple nuclear copies of mitochondrial tRNA (tRNA-lookalikes) has been observed in many higher organisms from human to the opossum suggesting the possibility that the lookalikes are functional. In humans, cytoplasmic tRNA genes can be grouped into 49 families according to their anticodon features. These genes are found on all chromosomes, except the 22 and Y chromosome. High clustering on 6p is observed (140 tRNA genes), as well as on chromosome 1. The HGNC, in collaboration with the Genomic tRNA Database (GtRNAdb) and experts in the field, has approved unique names for human genes that encode tRNAs. Typically, tRNA genes from Bacteria are shorter (mean = 77.6 bp) than those from Archaea (mean = 83.1 bp) and eukaryotes (mean = 84.7 bp). The mature tRNA follows an opposite pattern, with tRNAs from Bacteria being usually longer (median = 77.6 nt) than tRNAs from Archaea (median = 76.8 nt), with eukaryotes exhibiting the shortest mature tRNAs (median = 74.5 nt).
Sources: en.wikipedia.org
==== Pharmacokinetics ==== In the context of pharmacokinetics (how the body absorbs, metabolizes, and excretes a drug), the distribution coefficient has a strong influence on ADME properties of the drug. Hence the hydrophobicity of a compound (as measured by its distribution coefficient) is a major determinant of how drug-like it is. More specifically, for a drug to be orally absorbed, it normally must first pass through lipid bilayers in the intestinal epithelium (a process known as transcellular transport). For efficient transport, the drug must be hydrophobic enough to partition into the lipid bilayer, but not so hydrophobic, that once it is in the bilayer, it will not partition out again. Likewise, hydrophobicity plays a major role in determining where drugs are distributed within the body after absorption and, as a consequence, in how rapidly they are metabolized and excreted.
=== Subcellular localization === The c1orf27 protein is likely cytoplasmic. This was found with 55.5 reliability. The K-NN prediction was k = 9/23 and the protein was found to be 55.6% cytoplasmic, 11.1% mitochondrial, 11.1% vacuolar, 11.1% cytoskeletal, and 11.1% golgi.
=== Paramount and CBS partnership === On August 11, 2025, the UFC announced a seven-year media rights agreement with Paramount Skydance Corporation worth $7.7 billion. Paramount+ will exclusively stream all events for seven years, starting in 2026. Some numbered events will also air on CBS. The agreement will allow the UFC to move away from pay-per-view as events will stream on Paramount+ at no additional cost. All 13 of the UFC's flagship events and 30 Fight Nights a year will be streamed on the Paramount+ service. UFC CEO and President Dana White announced the UFC would produce four big events per year on CBS, and that the UFC's planned card for the White House on June 14th, 2026 would be one of those events.
Sources: en.wikipedia.org
== Clinical significance == In vascular smooth muscle cell (VSMC), ADAMTS7 mediates VSMC migration, which plays an essential role during the development of atherosclerosis and restenosis. This proatherogenic effect has been demonstrated to specifically require the catalytic protease activity of ADAMTS7, as mice expressing a catalytically inactive mutant of the enzyme (E373Q) are similarly protected against atherosclerosis. Adamts7 deficiency in both the Ldlr−/– and Apoe−/– hyperlipidemic mouse models markedly attenuates formation of atherosclerotic lesions; furthermore, wire-injury experiments in the Adamts7−/– mouse show reduced neointima formation. The association of ADAMTS7 with atherosclerosis suggests that inhibition of ADAMTS7 should be atheroprotective in humans. A negative correlation between the expression levels of specific miRNAs and ADAMTS7 is observed in normal tissues but not in disease tissues, implying an altered miRNA-target interaction in the disease state. Accordingly, expression profiles of these miRNAs and ADAMTS7 may be useful diagnostic tools to differentiate cancer and lichen planus from normal tissues. ADAMTS7 has also been identified as a putative oncogene and reported to be mutated exclusively in Asians, which may have implications for the prevention and treatment of hepatocellular carcinoma. In addition, ADAMTS7 plays a crucial role in the pathogenesis of arthritis. For example, the FGF2/p65/miR-105/Runx2/ADAMTS axis is reportedly involved in osteoarthritis (OA) pathogenesis.
American Chemical Society Award in Chromatography and Electrophoresis (1964) with Stanford Moore Richards Medal of the American Chemical Society (1972) with Stanford Moore Kaj Linderstrøm-Lang Award, Copenhagen (1972) with Stanford Moore The Nobel Prize in Chemistry (1972) with Stanford Moore and Christian B. Anfinsen
=== Interaction with drugs === In vitro testing suggests that unidentified wolfberry phytochemicals in goji tea may inhibit metabolism of medications, such as those processed by the cytochrome P450 liver enzymes, including such drugs as warfarin.
21CFR50.3: Code of Federal Regulations, Title 21--Food and Drugs, Chapter I--Food and Drug Administration, Department of Health and Human Services, Part 50--Protection of Human Subjects, Subpart A--General Provisions, Sec. 50.3 Definitions 21CFR312.3: Code of Federal Regulations, Title 21--Food and Drugs, Chapter I--Food and Drug Administration, Department of Health and Human Services, Part 312--Investigational New Drug Application, Subpart A--General Provisions, Sec. 312.3 Definitions and Interpretations, archived from the original on June 26, 2003 ICH E6: Guidance for Industry - E6 Good Clinical Practice: Consolidated Guidance (PDF), U.S. Department of Health and Human Services, Food and Drug Administration, April 1996, archived from the original (PDF) on July 9, 2009 ICH E9: Guidance for Industry - E9 Statistical Principles for Clinical Trials (PDF), U.S. Department of Health and Human Services, Food and Drug Administration, September 1998, archived from the original (PDF) on July 10, 2009 NCI: Dictionary of Cancer Terms, National Cancer Institute, archived from the original on 2008-10-25, retrieved 2008-10-05 NLM: Glossary of Clinical Trials Terms, U.S. National Library of Medicine, archived from the original on 2011-09-02, retrieved 2008-10-05
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.